Skip to main content
    M

    Milestone Pharmaceuticals Inc (MIST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.36
    -0.16 (-29.81%)

    Market Cap: $64.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Milestone Pharmaceuticals Inc (MIST) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Milestone Pharmaceuticals reported revenue of $1.55M for the fiscal year ended Dec 31, 2025. That year, net income was -$63.06M with a net margin of -4078.8%, operating cash flow was -$49.04M and free cash flow was -$49.34M. The quarter ended Sep 30, 2026 had revenue of $2.96M and net income of -$25.80M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.55MN/A100.0%-4019.4%-4078.8%
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$1.00M-80.0%100.0%-6109.8%-5968.5%
    Dec 2022$5.00M-66.7%100.0%-1192.8%-1167.8%
    Dec 2021$15.00MN/A100.0%-287.2%-285.7%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$1.55M$0$1.00M$5.00M$15.00M$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$0$8.00K
    Gross profit$1.55M$0$1.00M$5.00M$15.00M$0$0$0-$8.00K
    Research and development$18.11M$14.36M$31.05M$39.83M$38.67M$34.49M$41.98M$16.85M$5.64M
    Operating income-$62.14M-$42.10M-$61.10M-$59.64M-$43.07M-$50.71M-$57.88M-$23.82M-$8.27M
    Net income-$63.06M-$41.52M-$59.69M-$58.39M-$42.85M-$49.97M-$55.23M-$23.18M-$8.09M
    EBITDA-$61.59M-$41.63M-$60.76M-$59.55M-$42.98M-$50.61M-$57.84M-$23.81M-$8.26M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.96M$559.00K$238.00K$1.55M$0$0$0$108.00K$0$0$0-$868.00K
    Gross profit$2.64M$527.00K$224.00K$1.55M$0$0$0-$567.00K$0$0$0-$1.40M
    Operating income-$25.05M-$25.63M-$23.66M-$17.26M-$11.83M-$12.53M-$20.52M-$12.35M-$9.62M-$9.66M-$10.48M-$13.80M
    Net income-$25.80M-$28.61M-$26.07M-$17.41M-$11.92M-$12.97M-$20.76M-$12.36M-$9.44M-$9.36M-$10.35M-$13.61M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $57.84M by $15.21M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$113.56M$75.50M$75.23M$74.48M$119.85M$149.97M$123.43M$88.08M$27.59M
    Current assets$111.92M$73.93M$73.03M$71.80M$118.92M$148.69M$122.50M$88.05M$27.55M
    Cash and equivalents$73.05M$25.31M$13.76M$7.64M$114.14M$72.31M$119.82M$85.95M$10.88M
    Total liabilities$71.79M$62.35M$58.45M$8.13M$7.25M$6.86M$8.51M$4.53M$60.71M
    Short-term debt$647.00K$571.00K$546.00K$495.00K$224.00K$245.00K$330.00K$0$0
    Long-term debt$57.19M$53.35M$49.77M$0N/AN/AN/A$0$0
    Shareholder equity$41.77M$13.15M$16.77M$66.35M$112.60M$143.12M$114.92M-$55.21M-$33.12M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$162.69M$181.63M$193.73M$113.56M$87.75M$47.42M$61.88M$75.50M$82.71M$89.23M$96.00M$75.23M
    Total liabilities$168.91M$163.41M$157.69M$71.79M$67.25M$65.16M$68.01M$62.35M$58.69M$57.25M$56.08M$58.45M
    Cash and equivalents$144.47M$169.73M$71.32M$73.05M$46.69M$42.50M$45.09M$25.31M$12.80M$13.26M$10.13M$13.76M
    Shareholder equity-$6.22M$18.22M$36.05M$41.77M$20.50M-$17.75M-$6.12M$13.15M$24.01M$31.98M$39.92M$16.77M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$49.04M-$28.85M-$46.42M-$52.47M-$33.22M-$50.73M-$51.15M-$21.05M-$8.05M
    Capital expenditures$302.00K$33.00K$112.00K$272.00K$0$97.00K$413.00K$5.00K$36.00K
    Free cash flow-$49.34M-$28.88M-$46.54M-$52.74M-$33.22M-$50.83M-$51.56M-$21.05M-$8.09M
    Investing cash flow$11.25M$8.28M$4.76M-$57.12M$70.00M-$70.00M-$384.00K$16.00M-$16.02M
    Financing cash flow$85.53M$32.12M$47.79M$3.09M$5.05M$73.22M$85.41M$80.11M$30.72M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$25.24M-$22.71M-$16.05M-$12.78M-$9.75M-$12.57M-$13.95M-$6.84M-$7.02M-$6.05M-$8.93M-$9.80M
    Capital expenditures$4.00K$26.00K$45.00K$283.00K$2.00K$11.00K$6.00K$22.00K$4.00K$7.00K$0$31.00K
    Free cash flow-$25.25M-$22.74M-$16.10M-$13.06M-$9.75M-$12.58M-$13.96M-$6.87M-$7.02M-$6.06M-$8.93M-$9.83M
    Last 12 quarters

    Frequently Asked Questions About MIST

    What is Milestone Pharmaceuticals' annual revenue?

    Milestone Pharmaceuticals reported revenue of $1.55M for the fiscal year ended Dec 31, 2025.

    Is Milestone Pharmaceuticals profitable?

    No. Milestone Pharmaceuticals reported net income of -$63.06M for the fiscal year ended Dec 31, 2025, with a net margin of -4078.8%.

    How much free cash flow does MIST generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$49.04M minus capital expenditures of $302.00K produced free cash flow of -$49.34M.

    How much debt does Milestone Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $57.19M, short-term debt of $647.00K and cash and equivalents of $73.05M.

    What is MIST's profit margin?

    For the fiscal year ended Dec 31, 2025, Milestone Pharmaceuticals reported gross margin of 100.0%, operating margin of -4019.4% and net margin of -4078.8%.